These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 12611457)

  • 1. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
    Abraham DC; Jones RC; Jones SE; Cheek JH; Peters GN; Knox SM; Grant MD; Hampe DW; Savino DA; Harms SE
    Cancer; 1996 Jul; 78(1):91-100. PubMed ID: 8646731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
    Demartini WB; Lehman CD; Peacock S; Russell MT
    Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy.
    Wasser K; Sinn HP; Fink C; Klein SK; Junkermann H; Lüdemann HP; Zuna I; Delorme S
    Eur Radiol; 2003 Jun; 13(6):1213-23. PubMed ID: 12764635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prospective study on the role of MRI and B ultrasonography in evaluating the tumor response to neoadjuvant chemotherapy in breast cancer].
    Ye JM; Xu L; Wang DM; Zhao JX; Zhang LB; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2009 Mar; 47(5):349-52. PubMed ID: 19595011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
    Kwong MS; Chung GG; Horvath LJ; Ward BA; Hsu AD; Carter D; Tavassoli F; Haffty B; Burtness BA
    Cancer J; 2006; 12(3):212-21. PubMed ID: 16803680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.
    Roubidoux MA; LeCarpentier GL; Fowlkes JB; Bartz B; Pai D; Gordon SP; Schott AF; Johnson TD; Carson PL
    J Ultrasound Med; 2005 Jul; 24(7):885-95. PubMed ID: 15972702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
    Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
    Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy.
    Chen JH; Feig B; Agrawal G; Yu H; Carpenter PM; Mehta RS; Nalcioglu O; Su MY
    Cancer; 2008 Jan; 112(1):17-26. PubMed ID: 18000804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
    Loo CE; Teertstra HJ; Rodenhuis S; van de Vijver MJ; Hannemann J; Muller SH; Peeters MJ; Gilhuijs KG
    AJR Am J Roentgenol; 2008 Nov; 191(5):1331-8. PubMed ID: 18941065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy.
    Rieber A; Brambs HJ; Gabelmann A; Heilmann V; Kreienberg R; Kühn T
    Eur Radiol; 2002 Jul; 12(7):1711-9. PubMed ID: 12111062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study.
    Kim Y; Sim SH; Park B; Chae IH; Han JH; Jung SY; Lee S; Kwon Y; Park IH; Ko K; Lee CW; Lee KS; Kang HS; Lee ES
    Sci Rep; 2021 Jan; 11(1):634. PubMed ID: 33436702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
    Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
    Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
    Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
    Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
    Guo W; Zhang Y; Luo D; Yuan H
    Br J Radiol; 2020 Nov; 93(1115):20200751. PubMed ID: 32915647
    [No Abstract]   [Full Text] [Related]  

  • 20. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.